Johnnie Engelhardt Email

Cheif Engineer . AM Biotechnologies

Current Roles

Employees:
7
Revenue:
$1.1M
About
AM Biotechnologies, LLC is dedicated to the development and commercialization of aptamer technology and its products. Specifically, we develop synthetic affinity reagents called X-Aptamers for applications in life science research, diagnostics and therapeutics. X-Aptamers provide the performance of monoclonal antibodies but avoid many of the problems associated with them. An X-Aptamer is an affinity agent (similar in function to an antibody) that is comprised of a single strand of DNA with one or more (usually several) non-DNA chemical modifications attached to one or more of the DNA bases. An X-Aptamer has much greater chemical diversity than an aptamer. X-Aptamers use combinations of chemically-modified DNA bases and backbones that typically cannot be amplified using PCR. This makes it impossible to select X-Aptamers using the typical enzymatic processes used to select aptamers (e.g. SELEX). The diversity of the chemical functional groups in X-Aptamers provides much better interaction with a target, which typically results in better binding affinity and specificity.
AM Biotechnologies Address
12521 Gulf Freeway
Houston, TX
United States
AM Biotechnologies Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.